U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback